ライフサイエンスコーパス: survival benefit

1 participation in CR did confer a significant survival benefit.

2 reatic carcinoma and has shown a significant survival benefit.

3 ventricular tachycardia, but without proven survival benefit.

4 e magnitude of the reduction associated with survival benefit.

5 al, supporting the reported progression-free survival benefit.

6 lows tumor growth and provides a significant survival benefit.

7 into NSG mice and facilitated a significant survival benefit.

8 revascularization was a key mediator of the survival benefit.

9 a large reduction in transplantation-related survival benefit.

10 valve operation was not associated with late survival benefit.

11 HCC, with regard to transplantation-related survival benefit.

12 reatments for advanced disease offer limited survival benefit.

13 stratified ART timing are needed to maximize survival benefit.

14 wly diagnosed patients more likely to derive survival benefit.

15 was associated with a significant long-term survival benefit.

16 l-cell lung cancer (NSCLC) provides a modest survival benefit.

17 nsity statins were associated with a further survival benefit.

18 maintenance dialysis on the basis of limited survival benefit.

19 of docetaxel chemotherapy contributes to the survival benefit.

20 less was associated with significant midterm survival benefit.

21 arbazine, lomustine, and vincristine provide survival benefit.

22 ited States despite the lack of evidence for survival benefit.

23 , and current therapies provide only limited survival benefit.

24 tumor regression, and substantial long-term survival benefit.

25 ted with higher ORR, but no progression-free survival benefit.

26 1 or XPF antibodies did not confer any extra survival benefit.

27 al ligation and puncture failed to provide a survival benefit.

28 lantation outcomes and on transplant-related survival benefit.

29 has only provided a modest effect on overall survival benefits.

30 sess their benefits in terms of efficacy and survival benefits.

31 ellular carcinoma (HCC) but provides limited survival benefits.

32 iour to weaker stimuli, conferring potential survival benefits.

33 known reasons, adjuvant ADT provides further survival benefits.

34 ch shows that dairy consumption has positive survival benefits.

35 To evaluate the survival benefit achieved through surgical resection of

36 verdosing, trended toward an increase in the survival benefit afforded by BRAF inhibition.

37 he enrichment of Akkermansia species and the survival benefit after cecal ligation and puncture.

38 CXCL11 and sMICA may represent predictors of survival benefit after ipilimumab treatment as well as t

39 tients with treated HIV infection have clear survival benefits although with increased cardiac morbid

40 rophylactic co-trimoxazole seems to offer no survival benefit among HEU children in non-malarial, low

41 The degree of survival benefit among those managed surgically differed

42 gement of these disorders and the respective survival benefit and control of blood pressure.

43 ex, but lung transplant provides substantial survival benefit and markedly improved quality of life f

44 In summary, strong survival benefit and rapid control of SUDV replication b

45 ately selected, treatment for PCa results in survival benefits and toxicity profiles similar to those

46 Modest QOL benefit (without survival benefit) and high toxicity risk are associated

47 ssion is associated with both early and late survival benefits, and results in meaningful gains in li

48 atients suggest progression-free and overall survival benefits, application of the data to real-life

49 mproved PFS (arm B), with a modest trend for survival benefit (arm C) and increased toxicity reflecti

50 agents has been shown to convey significant survival benefit as a monotherapy, preclinical findings

51 A-incompatible live donors had a substantial survival benefit as compared with patients who did not u

52 for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance t

53 erature, and we thus sought to determine the survival benefit associated with a third kidney transpla

54 The amputation-free survival benefit associated with an endovascular revascu

55 The amputation-free survival benefit associated with an endovascular revascu

56 Primary outcome was the survival benefit associated with AVR.

57 hed cohort of 6,856 patients and confirmed a survival benefit associated with CRT (hazard ratio, 0.52

58 ssion used to determine which criteria had a survival benefit associated with HEMS.

59 A progression-free survival benefit associated with lenvatinib was observed

60 of neoadjuvant RT for patients with RPS, the survival benefit associated with this treatment modality

61 oth worlds": the excellent patency rates and survival benefits associated with the durable left inter

62 ctionation and treatment effect, the overall survival benefit being restricted to the hyperfractionat

63 ttle difference in 5-year transplant-related survival benefit between different age groups who had th

64 EVAR has an early survival benefit but an inferior late survival compared

65 suggest that adjuvant chemotherapy affords a survival benefit by directly targeting micrometastases.

66 response to detrimental microbes may provide survival benefits by allowing C. elegans to temporarily

67 etrimental effect on survival, but offers no survival benefit, by contrast with similar patients stud

68 idney transplantation (KT) has confirmed the survival benefit compared to remaining listed on dialysi

69 nalysis, 3KT demonstrated an overall patient survival benefit compared to the waitlist (hazards ratio

70 TCs), or adult trauma centers (ATCs) offer a survival benefit compared with one another when treating

71 We investigated whether EVAR had a long-term survival benefit compared with open repair.

72 atients, KT is associated with a significant survival benefit compared with remaining on dialysis.

73 animals treated with ITPP had a significant survival benefit compared with respective controls, whil

74 -KO mice treated with H2S showed no additive survival benefit compared with septic CHOP-KO mice.

75 andomly assigned to nivolumab had an overall survival benefit compared with those assigned to everoli

76 NAT followed by resection has a significant survival benefit compared with UR in early-stage, resect

77 Nonetheless, TAVR led to substantial survival benefits compared with standard therapy in both

78 dence is insufficient to support or refute a survival benefit conferred by early versus delayed ART i

79 Moreover, we demonstrate an immediate survival benefit conferred by the enhanced redox reactiv

80 Thereafter, the survival benefit decreased by 10% for every 15 min of tr

81 The time to survival benefit did not accrue until 8 months after tra

82 While these advances have led to limited survival benefit, evaluation of alternative modalities h

83 ed to noninvasive ventilation maintained the survival benefit even in studies allowing crossover of c

84 No significant survival benefit existed for greater extent of resection

85 ysis of survival from diagnosis identified a survival benefit favoring early HCT for both auto-HCT an

86 Although conferring a survival benefit, fever can negatively impact the functi

87 ocardial or cerebral ischemia, and conferred survival benefit following severe hemorrhage.

88 In a 22-center study, we estimated the survival benefit for 1025 recipients of kidney transplan

89 sponse to treatment and, more importantly, a survival benefit for a subset of head and neck cancer pa

90 No survival benefit for adjuvant HDI in patients with a sin

91 Total estimated population lifetime survival benefit for all persons starting ART during 200

92 ucted to date have failed to show an overall survival benefit for antiangiogenic agents alone or in c

93 10, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cance

94 Neoadjuvant treatment offers a significant survival benefit for clinical T3N0M0 esophageal cancer.

95 o used to estimate 5-year transplant-related survival benefit for different age groups, calculated as

96 However, costs relative to the survival benefit for differing treatment modalities used

97 ted through combination therapies to provide survival benefit for greater numbers of patients.

98 saw no progression-free survival or overall survival benefit for gross total resection compared with

99 We identified a progression-free survival benefit for gross total resection over sub-tota

100 Glucocorticosteroids were associated with a survival benefit for patients in all 3 analyses but were

101 Q NSCLC (CM017) that demonstrated an overall survival benefit for patients treated with nivolumab com

102 nonrate-responsive pacing (DDD) has shown no survival benefit for patients undergoing cardiac resynch

103 reduce rebleeding, but was associated with a survival benefit for patients with Child-Pugh class A or

104 vatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell

105 There is a lack of treatments providing survival benefit for patients with metastatic triple-neg

106 d regimens are associated with a substantial survival benefit for persons infected with hepatitis C v

107 Several studies have reported a survival benefit for polymyxin B hemoperfusion treatment

108 nd a randomized controlled trial reported no survival benefit for polymyxin B hemoperfusion treatment

109 espite these increased risks, KT may provide survival benefit for the HIV-infected patient with ESRD,

110 Helicopter transport does not impart a survival benefit for trauma patients when geographic con

111 de important insights into the durability of survival benefits for 2 process-of-care measures in curr

112 er, retrospective survival analysis revealed survival benefits for patients displaying immune respons

113 In LIPID, the absolute survival benefit from 6 years of pravastatin treatment a

114 diagnosed grade II or III glioma have shown survival benefit from adding chemotherapy to radiotherap

115 2 resections were more likely to demonstrate survival benefit from adjuvant chemoradiation.

116 e accurate individualized predictions of the survival benefit from adjuvant CIK cell treatment after

117 hin 30 to 40 days of treatment, suggesting a survival benefit from autophagy, permitting long-term pe

118 does it identify patients who have a greater survival benefit from CABG.

119 angina identified patients who had a greater survival benefit from CABG; and 3) whether CABG improved

120 predefined subgroups revealed a significant survival benefit from dexamethasone only for patients wi

121 atients with stage II disease who could gain survival benefit from fluorouracil-based adjuvant chemot

122 The survival benefit from HT increased progressively with hi

123 pients, although transplantation conferred a survival benefit from listing for only younger recipient

124 identified patients less likely to derive a survival benefit from primary prevention ICDs.

125 d patients with high comorbidity still had a survival benefit from renal transplantation.

126 up of 5.4 years (IQR 3.1-6.8) the event-free-survival benefit from the addition of trastuzumab to che

127 t nontrauma hospitals, despite evidence of a survival benefit from treatment at trauma centers.

128 with stage II CRC who could gain substantial survival benefits from fluorouracil-based adjuvant chemo

129 nt chemotherapy showed a substantial gain in survival benefits from the treatment (ie, recurrence red

130 Potential survival benefits from treating aggressive (Gleason scor

131 Although survival benefits have been shown at the population leve

132 To investigate whether the survival benefits have persisted, we performed the secon

133 When compared with PCI, CABG still showed a survival benefit (hazard ratio, 0.82; 95% confidence int

134 45, 95% CI 1.07-1.96, p=0.16) but no overall survival benefit (HR 1.23, 0.87-1.72, p=0.24).

135 Although sorafenib use was associated with a survival benefit (HR, 0.61; 95% CI, 0.47-0.79) among pat

136 ed human PBMCs exposed to UV-HSV-1 provide a survival benefit in a murine xenograft model of human ac

137 hat LVEF improvement is associated with less survival benefit in African Americans and women.

138 d low hepatotoxicity to provide a pronounced survival benefit in an aggressive genetic cancer model.

139 factor receptor (EGFR), which may provide a survival benefit in cancers.

140 the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafeni

141 the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafeni

142 thermore, D1-8 exhibits superior therapeutic survival benefit in influenza virus-infected mice compar

143 Transplantation provides a survival benefit in listed patients on VA-ECMO even if p

144 munotherapy study demonstrates a significant survival benefit in mCRC.

145 INTERPRETATION: We noted no survival benefit in men with metastatic castration-resis

146 ffects in MLL leukemia cells and substantial survival benefit in mouse models of MLL leukemia.

147 rapy in combination with DEB TACE may have a survival benefit in patients with advanced HCC.

148 Early revascularisation may offer a similar survival benefit in patients with and without renal dysf

149 dose of 45.0 to 50.4 Gy is associated with a survival benefit in patients with locally advanced recta

150 emotherapy was associated with a significant survival benefit in patients with newly diagnosed non-co

151 eous coronary intervention (PCI) may offer a survival benefit in patients with type 1 diabetes (T1D)

152 A recent meta-analysis demonstrated a survival benefit in post-infarction patients whose ventr

153 ies that neutralize toxin activity provide a survival benefit in preclinical animal models and preven

154 f adjuvant tamoxifen resulted in a long-term survival benefit in premenopausal patients with estrogen

155 ry channel, and TRPC4 inactivation confers a survival benefit in pulmonary arterial hypertension (PAH

156 atient safety and survival, with a potential survival benefit in RCTs using daily transmission verifi

157 Knowledge of survival benefit in relation to recipient age and comorb

158 owever, preliminary results have not shown a survival benefit in several of these trials.

159 eeded to further elucidate the potential for survival benefit in subgroups of patients.

160 Both TI and CLI TAVR have significant survival benefit in the context of standard therapy.

161 nship of morbid obesity with LT outcomes and survival benefit in the current era is unknown.

162 th immunotherapy, our findings suggest clear survival benefit in these patients.

163 SCC and to investigate whether HPV confers a survival benefit in these tumors.

164 results of long-term follow-up have found a survival benefit in this subgroup of patients.

165 Given the potential survival benefit in transplanting young adults and the s

166 There appears to be no overall 5-year survival benefit in treating S1 and S2 fibrosis patients

167 t-selective inhibitors provided considerable survival benefit in vivo.

168 more, in mice, inhibition of activin conveys survival benefits in pancreatitis.

169 indicated a lower rate of aspergillosis and survival benefits in patients with AML.

170 tiangiogenic therapies have failed to confer survival benefits in patients with metastatic breast can

171 TXA has demonstrated survival benefits in trauma patients in an international

172 High-flow nasal oxygen has recently shown survival benefits in unselected patients with acute resp

173 The 5-year survival benefit increased with actual MELD score for pa

174 n shown in randomised trials, but this early survival benefit is lost after a few years.

175 rtic aneurysm than with open repair, but the survival benefit is not sustained.

176 Symptomatic and survival benefit is noted in most patients when CaHD is

177 The survival benefit may be attributable to reduced immediat

178 A possible survival benefit might be offset by radiation-induced he

179 This survival benefit occurred in the first 30 days and persi

180 The South had the greatest survival benefit (odds ratio: 1.44; 95% confidence inter

181 he treatment regimen produced an incremental survival benefit of 0.15 life-years and 0.11 quality-adj

182 ristics associated with 3KT outcomes and the survival benefit of 3KT among recipients wait listed and

183 Everolimus was associated with a survival benefit of 6.3 months, although this finding wa

184 The survival benefit of a strategy of coronary-artery bypass

185 To characterize survival benefit of accepting IRD kidneys, we used 2010-

186 results suggest that there is a significant survival benefit of achieving an SVR compared with unsuc

187 Recent data have challenged the survival benefit of additional resection in patients wit

188 of MN must be balanced against the absolute survival benefit of adjuvant chemotherapy.

189 gram to enable individualized predictions of survival benefit of adjuvant CIK cell treatment for HCC

190 bout the actual severity of the stenosis and survival benefit of aortic valve replacement (AVR).

191 No progression-free survival benefit of AZD8931 compared with placebo was no

192 No overall survival benefit of bevacizumab was recorded (restricted

193 Although the potential survival benefit of bilateral internal mammary artery (B

194 , we aimed to assess if there is a long-term survival benefit of BIMA up to 10 years after coronary b

195 y utilization rates of CN and to examine the survival benefit of CN compared with non-CN patients tre

196 The survival benefit of CN was +0.7 and +3.6 months in patie

197 timulating factor-1 antibody compromised the survival benefit of dual therapy.

198 This study demonstrated a survival benefit of heart transplantation across all ran

199 The additional survival benefit of ipilimumab plus dacarbazine is maint

200 To determine the survival benefit of kidney transplantation in human immu

201 sh a counterfactual framework for estimating survival benefit of KT.

202 el, and the individual prediction of the ITT survival benefit of LT defined as the difference between

203 so, the concept of intention-to-treat (ITT) survival benefit of LT has been created.

204 l steps were used in order to create the ITT survival benefit of LT: the development of an ITT LT and

205 ng the conventional Cox model, an artificial survival benefit of metformin was detected (HR, 0.88; 95

206 The survival benefit of patients with HCC was similar to tha

207 The survival benefit of performing breast surgery for low-gr

208 III disease, there is no consensus about the survival benefit of postoperative chemotherapy in stage

209 However, the survival benefit of PTR for asymptomatic patients is con

210 There was a significant survival benefit of radiotherapy for younger patients wi

211 from a high-volume single center indicated a survival benefit of receiving a kidney transplant from a

212 ivo, B7H6-specific BiTE greatly enhanced the survival benefit of RMA/B7H6 lymphoma-bearing mice throu

213 We sought to determine the survival benefit of RT after BCS on the basis of risk fa

214 The survival benefit of RT was predominantly observed in sta

215 ngly, the S1P2 receptor mediated most of the survival benefit of S1P, whereas the endothelial S1P1 re

216 The survival benefit of systemic chemotherapy for the treatm

217 In this analysis, the survival benefit of the ICD exists but is attenuated wit

218 We previously showed a survival benefit of the implantable cardioverter defibri

219 enotype (70% v 27%; P < .001); any potential survival benefit of this genotype in patients age > 65 y

220 I/III studies are warranted to elucidate the survival benefit of this new therapy in patients with mC

221 However, the survival benefit of this treatment is modest, partly owi

222 present study was to analyze the chances and survival benefit of transplantation among patients in di

223 Uncertainty exists regarding potential survival benefits of bivalirudin compared with heparin w

224 Survival benefits of CRT versus RT alone increased in pa

225 Short-term survival benefits of endovascular aneurysm repair (EVAR)

226 Reciprocal transplants established that survival benefits of GSNOR deletion were attributable pr

227 The expected survival benefits of living over deceased donor transpla

228 Class I recommendation, although data on the survival benefits of rate control are lacking.

229 The survival benefits of weight gain after ART initiation ar

230 al revascularization seems to have long-term survival benefit on the basis of observational data but

231 The ability to recognize close kin confers survival benefits on single-celled microbes that live in

232 study period despite evidence suggesting no survival benefit over breast conservation.

233 study period despite evidence suggesting no survival benefit over breast conservation.

234 donor kidney transplants provide significant survival benefit over dialysis in waitlisted adults with

235 ction of tumour activity along with a marked survival benefit over either therapy alone.Our approach

236 dition, only r-ATG was associated with graft survival benefit over no-induction category (hazard rati

237 A 3KT achieves a survival benefit over remaining on the waitlist, althoug

238 h improvements in dietary quality did reveal survival benefits overall.

239 Whether this survival benefit persists after discharge is unknown.

240 The ITT transplant survival benefit presented here allows physicians to bet

241 The survival benefit progressively increased for 2-, 3-, 4-,

242 ey was associated with substantial long-term survival benefit; providers should consider this benefit

243 Lifetime per capita survival benefits ranged from 9.3 to 10.2 life-years acr

244 inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive pha

245 red by treatment, the net chance of a longer survival benefit remains high and tends to the cure rate

246 between ICD implantation and mortality with survival benefit seen only in the youngest patients.

247 th HCV remain concerning and motivate future survival benefit studies.

248 asing age does not affect transplant-related survival benefit substantially because age diminishes bo

249 sorafenib-resistant cells and showed better survival benefits than sorafenib in orthotopic HCC tumor

250 py, including surgery, experience an overall survival benefit that is unmatched by a surgery-first ap

251 r amelioration of disease symptoms and acute survival benefits, their full therapeutic potential is h

252 Adjuvant chemotherapy offers a survival benefit to a number of staging scenarios in non

253 ry alone, adjuvant chemoradiation provides a survival benefit to ESCC patients, especially those with

254 hibition (ARNI) therapy provided incremental survival benefit to patients with heart failure and redu

255 rmine whether there is improved disease-free survival benefit to taking the active drug in patients w

256 dates because it does not appear to confer a survival benefit to these candidates and may delay listi

257 e that many of these kidneys would provide a survival benefit to wait-listed patients.

258 oretical models that migration should confer survival benefits to evolve, and thus provide empirical

259 motherapeutic agent that provides additional survival benefits to patients with advanced disease.

260 ing risk regression and post-LT outcomes and survival benefit using Cox regression.

261 ndex with waitlist and post-LT outcomes, and survival benefit, using the United Network for Organ Sha

262 nts with decompensated cirrhosis, the median survival benefit was 31 days, and it was not cost-effect

263 The overall survival benefit was 62% versus 70% in deceased versus l

264 42; P <0.001), and statistically significant survival benefit was achieved by 194 days of KT.

265 HCC (21.8 +/- 8.0), a much lower mean 5-year survival benefit was achieved by providing liver transpl

266 nce, -0.84%; 95% CI: -1.11%, -0.57%), and no survival benefit was apparent (risk difference, -0.10%;

267 The survival benefit was associated with decreased serum con

268 d articles exploring the question of whether survival benefit was associated with maximal high-grade

269 Survival benefit was calculated as the difference betwee

270 Survival benefit was consistent across subgroups of pati

271 The survival benefit was consistent through all kidney funct

272 benefit from heart transplantation; however, survival benefit was delayed.

273 promising evidence of localized efficacy, no survival benefit was demonstrated.

274 The survival benefit was dose dependent, with the greatest e

275 A survival benefit was identified for patients who attende

276 , 1.20; 95% CI, 1.02-1.41; P=0.02), but this survival benefit was no longer present at 3 years (3.5%

277 < 0.004); however, statistically significant survival benefit was not achieved until 392 days after K

278 UVr in the residual lesion (P = .006), and a survival benefit was observed in patients with SUVr of l

279 However, an overall survival benefit was recorded in poor-prognosis patients

280 Preliminary evidence of an overall survival benefit was seen in an interim analysis; confir

281 The survival benefit was significant at 8 years across all l

282 d aspergillosis in BMT patients; however, no survival benefits were seen, and 1 trial indicated a low

283 rmine whether subjects triaged to HEMS had a survival benefit when actually transported by helicopter

284 or PET/CT scans were associated with minimal survival benefit when compared with clinical follow-up w

285 Based on evidence of survival benefit when initiating hemodialysis (HD) via a

286 m ventricular arrhythmias, would predict the survival benefit with an implantable cardioverter-defibr

287 nts alive 4 months after diagnosis derived a survival benefit with concurrent CRT over sequential CRT

288 with a QRSD >/=180 ms had a greater adjusted survival benefit with CRT-D versus standard ICD (hazard

289 OFT trials showed a significant disease-free survival benefit with exemestane plus ovarian function s

290 006 randomized trial demonstrated a 16-month survival benefit with intraperitoneal and intravenous (I

291 These results demonstrate a durable survival benefit with ipilimumab in advanced melanoma.

292 To demonstrate a long-term survival benefit with ipilimumab, we evaluated the 5-yea

293 Exploratory subgroup analysis suggested survival benefit with lestaurtinib in patients receiving

294 The survival benefit with nivolumab versus dacarbazine was o

295 The overall survival benefit with panobinostat over placebo with bor

296 trial in patients with hepatitis B found no survival benefit with periodic alpha-fetoprotein screeni

297 m third-party mice resulted in a significant survival benefit with retained graft-versus-tumor effect

298 The CONKO-003 phase III study reported a survival benefit with second-line fluorouracil (FU) and

299 uzumab (CLEOPATRA) study showed a 15.7-month survival benefit with the addition of pertuzumab to doce

300 ble for curative treatments and very limited survival benefits with the use of sorafenib, the current